The estimated Net Worth of Douglas Kakdl, L.P.Crestlin... is at least $589 Million dollars as of 12 February 2021. Douglas Crestlin owns over 2,216,798 units of Denali Therapeutics Inc stock worth over $270,389,359 and over the last 5 years Douglas sold DNLI stock worth over $318,153,125.
Douglas has made over 4 trades of the Denali Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Douglas sold 2,216,798 units of DNLI stock worth $144,091,870 on 12 February 2021.
The largest trade Douglas's ever made was selling 3,894,764 units of Denali Therapeutics Inc stock on 26 February 2020 worth over $78,868,971. On average, Douglas trades about 2,369,416 units every 88 days since 2020. As of 12 February 2021 Douglas still owns at least 9,984,836 units of Denali Therapeutics Inc stock.
You can see the complete history of Douglas Crestlin stock trades at the bottom of the page.
Over the last 7 years, insiders at Denali Therapeutics Inc have traded over $438,930,443 worth of Denali Therapeutics Inc stock and bought 275,000 units worth $4,950,000 . The most active insiders traders include Llc Fmr, Douglas Kakdl, L.P.Crestlin... und Jay T Flatley. On average, Denali Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,606,006. The most recent stock trade was executed by Vicki L Sato on 3 September 2024, trading 3,080 units of DNLI stock currently worth $77,000.
denali therapeutics inc. (“denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer’s disease, parkinson’s disease, als and others. denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. founding investors include fidelity biosciences, arch venture partners, flagship ventures and the alaska permanent fund (represented by crestline investors).
Denali Therapeutics Inc executives and other stock owners filed with the SEC include: